Construction of a Prognostic Model for Predicting Colorectal Cancer Prognosis and Response to Immunotherapy Based on Cuproptosis-Associated lncRNAs

Figure 6

GO and KEGG enrichment and drug sensitivity analysis between high-risk and low-risk groups. (a) GO analysis for the high-risk group and low-risk group. (b) KEGG analysis for the high-risk group and low-risk group. (c) Differences in chemosensitivity to cisplatin in high and low risk groups. (d) Differences in chemosensitivity to AZD8055 in high and low risk groups. (e) Differences in chemosensitivity to paclitaxel in high and low risk groups. (f) Differences in chemosensitivity to 5-Fluorouracil in high and low risk groups. (g) Differences in sensitivity to AKT inhibitor III treatment between high and low-risk groups. (h) Differences in sensitivity to trametinib treatment between high- and low-risk groups. Sensitivity to chemotherapeutic drugs is expressed by the half inhibitory centration (IC50) of chemotherapeutic drugs.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)